{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:49:34Z","timestamp":1783748974451,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T00:00:00Z","timestamp":1405641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.schres.2014.07.015","type":"journal-article","created":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T09:46:09Z","timestamp":1406799969000},"page":"213-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia"],"prefix":"10.1016","volume":"158","author":[{"given":"Kotaro","family":"Hatta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Otachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyoshi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takebayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemasa","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Nakase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2014.07.015_bb0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/NDT.S30268","article-title":"Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia","volume":"8","author":"Ascher-Svanum","year":"2012","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.schres.2014.07.015_bb0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","article-title":"Sex, race, and smoking impact olanzapine exposure","volume":"48","author":"Bigos","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.schres.2014.07.015_bb0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JCP.0b013e31828b28d5","article-title":"Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response","volume":"33","author":"Bishara","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2014.07.015_bb0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/JCP.0b013e3181d2193c","article-title":"Antipsychotic drug treatment in first-episode psychosis should patients be switched to a different antipsychotic drug after 2, 4, or 6weeks of nonresponse?","volume":"30","author":"Derks","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.schres.2014.07.015_bb0025","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.07.015_bb0030","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"4","key":"10.1016\/j.schres.2014.07.015_bb0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s004060050036","article-title":"Abnormal physiological conditions in acute schizophrenic patients on emergency admission: dehydration, hypokalemia, leukocytosis and elevated serum muscle enzymes","volume":"248","author":"Hatta","year":"1998","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2014.07.015_bb0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.schres.2009.05.030","article-title":"Effectiveness of second-generation antipsychotics with acute-phase schizophrenia","volume":"113","author":"Hatta","year":"2009","journal-title":"Schizophr. Res."},{"issue":"1-3","key":"10.1016\/j.schres.2014.07.015_bb0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2011.02.011","article-title":"Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia","volume":"128","author":"Hatta","year":"2011","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2014.07.015_bb0040","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.psychres.2012.01.006","article-title":"A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone","volume":"198","author":"Hatta","year":"2012","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.schres.2014.07.015_bb0055","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.psychres.2013.07.005","article-title":"The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia","volume":"210","author":"Hatta","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2014.07.015_bb0060","series-title":"Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage","author":"Inada","year":"1996"},{"issue":"5","key":"10.1016\/j.schres.2014.07.015_bb0065","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1192\/bjp.166.5.654","article-title":"A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF)","volume":"166","author":"Jones","year":"1995","journal-title":"Br. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2014.07.015_bb0070","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.07.015_bb0075","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2013.10.034","article-title":"Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary","volume":"152","author":"Katona","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.07.015_bb0080","series-title":"Positive and Negative Syndrome Scale (PANSS) Rating Manual","author":"Kay","year":"1991"},{"issue":"2","key":"10.1016\/j.schres.2014.07.015_bb0085","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","article-title":"Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia","volume":"35","author":"Kinon","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl. 438","key":"10.1016\/j.schres.2014.07.015_bb0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","article-title":"Definitions of response and remission in schizophrenia: recommendations for their use and their presentation","volume":"119","author":"Leucht","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"9896","key":"10.1016\/j.schres.2014.07.015_bb0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"2\u20133","key":"10.1016\/j.schres.2014.07.015_bb0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.schres.2012.08.030","article-title":"Early symptom response to antipsychotic medication as a marker of subsequent symptom change: An eighteen-month follow-up study of recent episode schizophrenia","volume":"141","author":"Levine","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.07.015_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007474.pub2","article-title":"Risperidone dose for schizophrenia","volume":"4","author":"Li","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.schres.2014.07.015_bb0110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin. Pharmacokinet."},{"issue":"4\u20135","key":"10.1016\/j.schres.2014.07.015_bb0115","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/hup.1200","article-title":"Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies","volume":"26","author":"O\u2019Gorman","year":"2011","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"issue":"4","key":"10.1016\/j.schres.2014.07.015_bb0120","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0b013e318221b408","article-title":"Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009","volume":"31","author":"Patel","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2014.07.015_bb0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2014.07.015_bb0130","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","article-title":"Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia","volume":"137","author":"Wallwork","year":"2012","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414003727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414003727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T07:51:32Z","timestamp":1538380292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414003727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":26,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0920996414003727"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.07.015","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}